REG - Craneware plc - Result of AGM

CranewareAnnouncement

Wed 16:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250820:nRST1424Wa&default-theme=true

RNS Number : 1424W  Craneware plc  20 August 2025

Craneware plc

("Craneware" or the "Company")

 Result of General Meeting

 

20 August 2025 - Craneware (AIM: CRW.L), a leader in healthcare financial
performance solutions, announces that at a general meeting of the Company (the
"General Meeting") held earlier today, at Tanfield House, 1 Tanfield,
Edinburgh, EH3 5DA, UK, the resolutions to approve the proposed capital
reduction were voted on by shareholders, by way of a poll, and were duly
approved.

Details of the resolutions were set out in the circular posted to shareholders
on 1 August 2025 which can also be found on the Company's website at
www.thecranewaregroup.com.

 No.  Resolution                                                                       Votes For ((a))    % For    Votes Against  % Against  Votes Withheld ((b))  Total
 1    To capitalise the merger reserve of the Company and authorise the directors to
      allot unissued B ordinary shares

                                                                                       24,506,336         100.00   343            0.00       4,665                 24,511,344
 2    To set out the rights and restrictions attaching to the B ordinary shares        24,510,788         100.00   343            0.00       213                   24,511,344
 3    To reduce the capital of the Company by cancelling and extinguishing the B
      Ordinary Shares allotted and issued pursuant to resolution 1 and to credit the

      amount of such reduction to the reserves of the Company

                                                                                       24,511,131         100.00   0              0.00       213                   24,511,344
 4    To cancel the share premium account of the Company and to credit the amount of
      such reduction to the reserves of the Company

                                                                                       24,511,131         100.00   0              0.00       213                   24,511,344

 

Notes:

(a)   The 'For' votes include those proxy votes which gave the Chair
discretion.

(b)   A vote withheld is not a vote in law and is not counted in the
calculation of the votes 'For' or 'Against' the resolution.

(c)    All resolutions put to the General Meeting were special resolutions.

 

The total number of Ordinary Shares of the Company in issue (excluding shares
held in Treasury)  on 18 August 2025, the deadline for casting votes by proxy
in advance of the General Meeting, was 35,409,802 Ordinary Shares.  69.22 per
cent of the total voting rights in the Company was instructed in respect of
the resolutions put to the General Meeting.

The Company's shareholders should note that the proposed reduction of capital
is conditional upon confirmation being obtained from the Court of Session,
Edinburgh, Scotland (the "Court").

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

 Expected date of the first Court hearing for initial directions                in or around late August 2025
 Capital Reduction Record Time                                                  6.30 p.m. on the Business Day

                                                                                preceding the Court hearing to confirm the Reduction of Capital
 Expected date of the second Court hearing to confirm the Reduction of Capital  in or around October 2025
 Effective Date of the Reduction of Capital                                     Business Day after the Court order

                                                                                confirming the Reduction of Capital

 

Notes: Each of the times and dates, as set out in the Expected Timetable of
Principal Events above, is based on current expectations and is subject to
change. If any of the above times and/or dates is changed, the revised times
and/or dates will be notified to Shareholders by announcement through a
regulatory information service. All above references to times are to London
times.

 

For further information, please contact:

 

 Craneware plc                                     +44 (0)131 550 3100
 Keith Neilson, CEO
 Craig Preston, CFO

 Alma Strategic Communications (Financial PR)      +44 (0)20 3405 0205
 Caroline Forde, Kinvara Verdon, Sarah Peters      craneware@almastrategic.com

 Peel Hunt (NOMAD and Joint Broker)                +44 (0)20 7418 8900
 Neil Patel, Benjamin Cryer, Kate Bannatyne

 Investec Bank PLC (Joint Broker)                  +44 (0)20 7597 5970
 Patrick Robb, Virginia Bull, James Smith
 ( )                                               ( )
 Berenberg (Joint Broker)                          +44 (0)20 3207 7800
 Mark Whitmore, Richard Andrews, Patrick Dolaghan

 

About The Craneware Group

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in
healthcare financial and operational transformation, delivering cutting-edge
technologies that drive measurable impact. Our Trisus(®) cloud ecosystem
unifies data, revenue intelligence, margin intelligence, and advanced
analytics, enabling healthcare organizations to optimize performance, improve
financial sustainability, and drive strategic growth.

As a trusted Microsoft partner, we provide future-ready solutions-including
the Best in KLAS Trisus Chargemaster-that simplify the complexities of
healthcare finance and operations. What sets us apart is our unique
combination of deep healthcare expertise and engineering excellence,
positioning us as a strategic partner rather than just a technology provider.

The Craneware Group empowers healthcare organizations to achieve sustainable
financial success while delivering better outcomes for the communities they
serve-today and in the future. Together, we are transforming the business of
healthcare.

Learn more at www.thecranewaregroup.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGBUGDILDDDGUG